; (B) the number, nature, and kind of designated State medical cannabis products granted or denied certification in the previous year; (C) any variances or lingering potential conflicts with State laws regarding medical cannabis products and section 301 of this Act (and the amendments made by such section), and any plans for resolving these variances; and (D) the impact of section 301 of this Act (and the amendments made by such section) with respect to patient access to designated State medical cannabis products. (2) Cannabidiol (cbd) and other hemp-derived cannabinoids market and safety report A report detailing— (A) what the current market for cannabidiol (hereainfter referred to as CBD ) and other hemp-derived cannabinoid products looks like, including the types and forms of products available, manufacturing practices within the industry, market supply chain, how products are marketed and sold, the types of cannabinoids used in products, the marketed effects of CBD and other hemp-derived cannabinoid products, and the range of CBD and other hemp derived cannabinoid doses currently found in the market; (B) what State-based regulations have been created to CBD and other hemp derived cannabinoids and what is their interaction with Agricultural Marketing Act of 1946 in general, including Public Law 115–334 , the Agriculture Improvement Act of 2018 ( the 2018 Farm Bill ); (C) how the lack of national standards for CBD and other hemp derived cannabinoid products affects the market